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Introduction
Renal function and blood pressure are tightly linked and
hypertension per se is a risk factor for the development
of end-stage renal disease (ESRD)
1, 2). The renin-angioten
-sin-aldosterone system (RAAS) is a key regulator of both
blood pressure and renal function, so that genes encoding
components of the RAAS can be candidate genes for evalu-
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ating predisposition for the development of hypertension,
cardiovascular disease and progression of renal disease.
Polymorphisms have been described in the genes encoding
several important components of the RAAS, including an-
giotensinogen
3), angiotensin-converting enzyme
4), angio-
tensin type receptors І
5), and aldosterone synthase
6).
The aldosterone synthase gene, CYP11B2, encodes for
a cytochrome P450 enzyme, involved in the terminal steps
of aldosterone synthesis in the zona glomerulosa cells of
human adrenal glands and its expression is regulated by
angiotensin II and potassium
7). The CYP11B2 -344C/T
polymorphism, which is located at a putative binding site
for the steroidogenic transcription factor (SF-1), has been
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Aldosterone synthase gene (CYP11B2) -344C/T polymorphism has been reported to be associated with
serum aldosterone level, urinary aldosterone excretion, blood pressure, and left ventricular size and mass.
The aim of this study was to evaluate the relation between CYP11B2 polymorphism and end-stage renal
disease (ESRD) in the Korean population and the association with CYP11B2 polymorphism and car-
diovascular morbidity in ESRD patients on hemodialysis. Genotyping was performed in 134 control subjects
and 271 ESRD patients for CYP11B2 polymorphism using polymerase chain reaction through subsequent
cleavage with restriction enzyme. Also current blood pressure, demographic, anthropometric and biochemical
variables were investigated. The genotype distribution did not differ between ESRD patients and controls
and there were no significant differences in blood pressure, use of antihypertensive medication, left ven-
tricular hypertrophy and cardiovascular disease among the three genotypes in ESRD patients on hemodialysis.
Our findings do not support the hypothesis that CYP11B2 polymorphism may be associated with prevalence
of ESRD and suggest that CYP11B2 polymorphism may not be a genetic marker for cardiovascular morbidity
in Korean ESRD patients.
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reported to be associated with serum aldosterone level
8),
urinary aldosterone excretion
9), blood pressure
9-12), left ven-
tricular size and mass
13, 14). However, there were few stud-
ies on the association of CYP11B2 -344C/T polymor-
phism and renal function, which has inconsistent results
15,
16). The aim of this study is to evaluate the relation be-
tween CYP11B2 polymorphism and ESRD in the Korean
population and the association with CYP11B2 poly-
morphism and cardiovascular morbidity in ESRD patients
on hemodialysis.
Methods
1. Subjects
The study subjects were 271 ESRD patients on main-
tenance hemodialysis over three months from dialysis cen-
ters located in the western district of Seoul, Korea and
134 control subjects without renal disease from Korea
University Guro Hospital. The controls were individuals
who have had no medical history and were normal in blood
pressure, blood chemistry, urinalysis, and electrocardio-
gram (EKG).
Basic demographic data, current blood pressure, in-
formation on underlying renal disease, previous cardiova-
scular disease, and current antihypertensive medication
were obtained for all ESRD subjects. Left ventricular hy-
pertrophy was determined as the voltage sum SV1+ (RV5
or RV6) 35 mm using the Sokolow-Lyon voltage criteria
on EKG
17). Clinical cardiovascular diseases include ische-
mic heart disease, cerebrovascular disease and congestive
heart failure. Ischemic heart disease was considered if the
patient had previous myocardial infarction, positive coro-
nary angioplasty or other diagnostic procedure (e.g. ex-
ercise test, thallium or dobutamine stress test) or the pres-
ence of ischemic change on the resting EKG (as distinct
from left ventricular hypertrophy). Cerebrovascular disease
was established if the patient had a history of transient
ischemic attacks or stroke verified by computed tomog-
raphy, or carotid artery stenosis greater than 70% verified
by doppler ultrasound. Congestive heart failure was de-
fined as clinical evidence of pulmonary edema, not attribut-
able to errors in fluid balance, and/or moderate to severe
left ventricular dysfunction on echocardiography (left ven-
tricular ejection fraction <45%). In addition, biochemical
data including plasma hemoglobin, hematocrit, serum albu-
min, creatinine, glucose, total cholesterol, total calcium,
phosphorus, intact parathyroid hormone, and single-pool
Kt/V were obtained.
2. Genotyping
Genomic DNA was extracted from peripheral blood using
the DNA extraction kit (G-Dex
TM IIb No.17241, iNtRON).
Genotypes were determined by polymerase chain reaction
(PCR) amplification of the promoter region of the CYP11B2
gene using the oligonucleotide primers (upstream: 5'-CAG
GAGGAGACCCCATGTGAC-3'; downstream: 5'-CCTCC
ACCCTGTTCAGCCC-3'). PCR conditions were: initial de-
naturation at 94 C for 3 min; then 32 cycles at 94 C for
1 min, at 60 C (annealing) for 1 min, and at 72 C (extension)
for 1 min. Restriction fragment length polymorphism (RFLP)
was performed by adding 10 U of restriction endonuclease
HaeIII site in the appropriated buffer to 5 µL from each
reaction (a 537 bp product) and by incubating at 37 C for
2 hours. The samples digested then underwent electro-
phoresis on 2.5% agarose gel with a Gel Electrophoresis
Apparatus, ethidium bromide stained, and analyzed under
UV lights. Since the (-344)T allele lacks an HaeIII site
(GGCC) present in the (-344)C allele, the (-344)T alleles
are detected as fragments of 273 bp and (-344)C alleles
as fragments of 202 bp (plus smaller fragment in each case)
(Fig. 1).
3. Statistical analysis
Statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS-12.0, Chicago, Illinois,
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USA). Values are expressed as mean±standard deviation
(SD) or percentage. Statistical differences between means
were assessed by t test or analysis of variance (ANOVA)
for analysis of continuous variables. For categorical varia-
bles, the 2×2 contingency table χ
2 test was used. To exam-
ine the independent contribution of CYP11B2 poly-
morphism and estimate the odds ratio, while adjusting for
the effects of other clinical characteristics, we used a logis-
tic analysis. The Hardy-Weinberg equilibrium was tested
by a χ
2 test. P values below 0.05 were considered statisti-
cally significant.
Results
The baseline characteristics of controls and ESRD pa-
tients are summarized in Table 1. The mean age and male
prevalence were similar between controls and ESRD pa-
tients. Genotype and allele frequencies for the poly-
morphism of CYP11B2 in controls and ESRD patients are
presented in Table 2. The controls and ESRD patients were
in Hardy-Weinberg equilibrium for the polymorphism.
Genotype distribution of CYP11B2 polymorphism did not
differ between controls and ESRD patients.
Table 3 shows the comparison of clinical and bio-
chemical characteristics of ESRD patients according to
genotypes of CYP11B2 polymorphism. We could observe
the differences in systolic blood pressure and frequency
of diabetes among the three genotypes in this analysis.
However, these findings were not significant after adjust-
ment for age and sex. In addition, there was no association
of CYP11B2 polymorphism with left ventricular hyper-
trophy or cardiovascular disease in ESRD patients (Table
4).
Discussion
Our study was designed to test the hypothesis that the
prevalence of renal failure may be influenced by gene poly-
morphism of the RAAS, especially aldosterone synthase
gene polymorphism. In this cross-sectional study, we could
not observe significant differences in the genotype and al-
lele frequency of the CYP11B2 -344C/T polymorphism
between controls and ESRD patients. Previous studies per-
formed in Europe showed inconsistent results. Lovati et
Table 1. Baseline Characteristics of Controls and End-Stage
Renal Disease Patients
Characteristics Controls
(n=134)
Patients
(n=271)
Age (years)
Sex (male%/female%)
Body mass index (kg/m
2)
Hemodialysis duration (years)
Cause of renal failure (%)
Diabetic nephropathy
Hypertensive nephrosclerosis
Chronic glomerulonephritis
Polycystic kidney disease
Others
Unknown
Smoking (%)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Use of antihypertensive drugs (%)
0 / 1 / 2 /
3 / 4 / 5
Left ventricular hypertrophy (%)
Cardiovascular disease (%)
Hemoglobin (g/dL)
Hematocrit (%)
Serum albumin (g/dL)
Serum creatinine (mg/dL)
Serum glucose (mg/dL)
Serum total cholesterol (mg/dL)
Serum total calcium (mg/dL)
Serum phopshorus (mg/dL)
Intact parathyroid hormone (pg/mL)
Kt/V
53.0±10.7
55.0/45.0
23.1±2.9
-
-
NA
116.0±12.3
70.8±8.8
0
0
0
13.6±1.5
41.9±3.9
4.9±0.2
0.9±0.2
93.3±10.4
187.4±32.2
9.6±0.4
3.7±0.4
NA
-
54.1±13.2
54.2/45.8
21.5±3.1
4.3±3.6
36.9
20.3
8.5
3.0
1.8
22.5
20.8
156.1±21.2
90.3±7.3
73.1
26.9/17.0/22.9/
18.8/13.7/0.7
35.3
20.7
10.2±1.2
31.2±3.7
4.0±0.3
9.9±2.7
121.6±54.9
149.0±33.0
8.8±0.8
5.3±1.7
118.6±159.5
1.5±0.3
NA, Not available.
Table 2. Genotype and Allele Frequencies of the CYP11B2
Polymorphism in Controls and ESRD Patients
Controls
(n=134)
ESRD
(n=271)
N (%) N (%) OR* (95% CI)
Genotype
TT
TC
CC
Allele
%T
%C
59 (44.0)
64 (47.8)
11 (8.2)
0.68
0.32
130 (48.0)
115 (42.4)
26 (9.6)
0.69
0.31
1.00 (reference)
0.82 (0.53-1.26)
1.04 (0.48-2.26)
P=0.613
1.00 (reference)
0.94 (0.68-1.28)
P=0.675
CYP11B2, aldosterone synthase; ESRD, end-stage renal disease.
*Adjusted odds ratio for age and sex.70 Electrolyte Blood Press 7:67-72, 2009
al. reported that there was no association between the
CYP11B2 genotype and progression of renal failure among
the ESRD patients
15). On the other hand, Fabris et al. report
ed that significant association was found between the
CYP11B2 gene polymorphism and renal insufficiency in
the hypertensive population
16). They observed an increased
proportion of CC genotype in hypertensive patients with
renal damage compared with hypertensive patients without
renal damage. The adjusted odds ratio was 3.89 for
CYP11B2 -344C allele as a recessive effect. However,
CYP11B2 genotypes were not in Hardy-Weinberg equili-
brium among controls in Fabris and colleagues' report, so
linkage disequlibrium in control subjects weakens a causal
interpretation of these statistically significant findings.
Controls in our study are of the normotensive healthy pop-
ulation and show similar allele frequency in comparison
with another Korean study (T allele frequency 0.69)
18). In
the Korean population, there has been research aimed at
evaluating the association between CYP11B2 poly-
morphism and hypertension
18), myocardial infarction
19),
and risk of coronary in-stent restenosis
20). To our knowl-
edge, this is the first report about the CYP11B2 C-344T
allele frequency in Korean ESRD patients.
Several studies of the association between this poly-
morphism and hypertension
12, 21, 22), left ventricle size and
mass
13, 23), arterial stiffness
24), and myocardial infarction
14,
25) in the general population and hypertensive individuals
with normal renal function have been performed. In ESRD
patients, however, studies of association of CYP11B2
-344C/T polymorphism and left ventricular hypertrophy
and cardiovascular morbidity are few. Our results did not
show significant differences in left ventricular hypertrophy
by EKG criteria and cardiovascular disease among the
three genotypes in ESRD patients. We think this lack of
association is due to not only limitation of the study, but
Table 3. Comparison of Clinical and Biochemical Characteristics of End-Stage Renal Disease Patients according to CYP11B2
Polymorphism
TT (n=130) TC (n=115) CC (n=26) P
Age (years)
Sex (%male)
Body mass index (kg/m
2)
Hemodialysis duration (years)
Diabetes (%)
Smoking (%)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Use of antihypertensive drugs (%)
Left ventricular hypertrophy (%)
Previous cardiovascular disease (%)
Hemoglobin (g/dL)
Serum albumin (g/dL)
Serum creatinine (mg/dL)
Serum total cholesterol (mg/dL)
Serum total calcium (mg/dL)
Serum phosphorus (mg/dL)
Intact parathyroid hormone (pg/mL)
Kt/V
53.9±13.7
51.5
21.4±3.0
4.5±3.4
26.2
19.8
158.4±19.7
90.9±7.3
74.6
30.2
19.2
10.3±1.1
4.1±0.3
9.9±2.9
152.5±32.6
8.8±0.9
5.4±1.9
123.0±182.5
1.5±0.3
53.6±13.1
55.7
21.6±3.4
4.3±3.9
40.0
23.1
152.2±23.0
89.7±7.7
70.4
37.8
20.9
10.1±1.2
4.0±0.3
9.8±2.7
146.3±32.8
8.8±0.7
5.2±1.7
116.7±124.5
1.4±0.3
57.8±11.7
61.5
21.4±3.0
3.4±2.8
42.3
16.0
162.2±17.3
90.4±5.6
76.9
48.0
26.9
9.7±1.1
3.9±0.2
10.4±2.1
149.8±35.7
8.8±0.8
5.1±1.3
105.8±174.9
1.4±0.2
0.326
0.597
0.918
0.359
0.044
0.689
0.041
0.515
0.684
0.181
0.675
0.057
0.067
0.688
0.354
0.936
0.659
0.882
0.156
CYP11B2, aldosterone synthase.
Table 4. Adjusted Odds Ratio for Left Ventricular Hyper-
trophy and Cardiovascular Disease by CYP11B2 Genotype
Left ventricular
hypertrophy
Cardiovascular
disease
Genotype OR* (95% CI) OR* (95% CI)
TT
TC
CC
1.00 (reference)
1.41 (0.75-2.66)
1.78 (0.67-4.70)
1.00 (reference)
1.00 (0.50-2.01)
1.16 (0.40-3.32)
P=0.393 P=0.960
CYP11B2, aldosterone synthase.
*Adjusted odds ratio for age, sex, body mass index, hemo-
dialysis duration, smoking, hypertension, diabetes, hemoglobin,
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also multifactorial etiology of cardiovascular morbidity in
ESRD patients. The limitations of this present study are
the insufficient statistical power as a result of a relatively
small number of patients and the use of the EKG instead
of echocardiographic examination for diagnosis of left ven-
tricular hypertrophy. We obtained age and sex adjusted
odds ratio using logistic regression methods because we
could not match each individual case to his or her own
control. It is also possible that the ESRD patients with
high risk genotype may be excluded from the present study
because of premature mortality due to cardiovascular influ-
ences by CYP11B2 polymorphism. Thus, further pro-
spective investigation with sufficient statistical power is
needed to explore the role of CYP11B2 polymorphism in
the susceptibility of ESRD and cardiovascular effect in
ESRD patients.
In conclusion, our findings do not support the hypothesis
that CYP11B2 polymorphism is associated with prevalence
of ESRD and suggest that CYP11B2 polymorphism may
not be a genetic marker for cardiovascular morbidity in
Korean ESRD patients.
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